Agios Pharmaceuticals
AGIO
220 hedge funds and large institutions have $1.76B invested in Agios Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 73 increasing their positions, 79 reducing their positions, and 39 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
0.05% less ownership
Funds ownership: 104.94% → 104.89% (-0.05%)
4% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $11.1M
5% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 39
8% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 79
2% less funds holding
Funds holding: 224 → 220 (-4)
10% less capital invested
Capital invested by funds: $1.97B → $1.76B (-$204M)
Top Buyers
| 1 |
CC
Commodore Capital
New York
|
+$72.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$24.2M |
| 3 |
SCM
SCS Capital Management
Boston,
Massachusetts
|
+$20.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.6M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.4M |
Top Sellers
| 1 |
JFG
Jefferies Financial Group
New York
|
-$49.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$35.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18.9M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$13.7M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$9.08M |
AGIO Hedge Fund Activity: Q1 2025 in Review
220 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2025, worth a combined $1.76B — down 10% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of AGIO and 37 opened new positions — a net loss of 2 holders — while 79 trimmed existing stakes and 73 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $72.5M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $49.3M sold.
- 220 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2025, down from 224 in Q4 2024.
- Funds reported $1.76B of Agios Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
- 37 funds opened new Agios Pharmaceuticals positions in Q1 2025 and 39 closed out, a net change of -2 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2025 was Commodore Capital, an estimated $72.5M added.
- The largest Agios Pharmaceuticals seller in Q1 2025 was Jefferies Financial Group, an estimated $49.3M sold.
Based on aggregated 13F filings for Q1 2025.